177 related articles for article (PubMed ID: 37039251)
1. Control of human pancreatic beta cell kinome by glucagon-like peptide-1 receptor biased agonism.
Xiao J; El Eid L; Buenaventura T; Boutry R; Bonnefond A; Jones B; Rutter GA; Froguel P; Tomas A
Diabetes Obes Metab; 2023 Aug; 25(8):2105-2119. PubMed ID: 37039251
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of efficacy- versus affinity-driven agonism with biased GLP-1R ligands P5 and exendin-F1.
Marzook A; Chen S; Pickford P; Lucey M; Wang Y; Corrêa IR; Broichhagen J; Hodson DJ; Salem V; Rutter GA; Tan TM; Bloom SR; Tomas A; Jones B
Biochem Pharmacol; 2021 Aug; 190():114656. PubMed ID: 34129856
[TBL] [Abstract][Full Text] [Related]
3. Acylation of the Incretin Peptide Exendin-4 Directly Impacts Glucagon-Like Peptide-1 Receptor Signaling and Trafficking.
Lucey M; Ashik T; Marzook A; Wang Y; Goulding J; Oishi A; Broichhagen J; Hodson DJ; Minnion J; Elani Y; Jockers R; Briddon SJ; Bloom SR; Tomas A; Jones B
Mol Pharmacol; 2021 Oct; 100(4):319-334. PubMed ID: 34315812
[TBL] [Abstract][Full Text] [Related]
4. Glucagon-like peptide-1 receptor internalisation controls spatiotemporal signalling mediated by biased agonists.
Fletcher MM; Halls ML; Zhao P; Clydesdale L; Christopoulos A; Sexton PM; Wootten D
Biochem Pharmacol; 2018 Oct; 156():406-419. PubMed ID: 30195733
[TBL] [Abstract][Full Text] [Related]
5. Association of glucagon-like peptide-1 receptor-targeted imaging probe with in vivo glucagon-like peptide-1 receptor agonist glucose-lowering effects.
Murakami T; Fujimoto H; Fujita N; Hamamatsu K; Yabe D; Inagaki N
J Diabetes Investig; 2020 Nov; 11(6):1448-1456. PubMed ID: 32323451
[TBL] [Abstract][Full Text] [Related]
6. Activation of Glucagon-Like Peptide-1 Receptor Promotes Neuroprotection in Experimental Autoimmune Encephalomyelitis by Reducing Neuroinflammatory Responses.
Lee CH; Jeon SJ; Cho KS; Moon E; Sapkota A; Jun HS; Ryu JH; Choi JW
Mol Neurobiol; 2018 Apr; 55(4):3007-3020. PubMed ID: 28456941
[TBL] [Abstract][Full Text] [Related]
7. Disconnect between signalling potency and in vivo efficacy of pharmacokinetically optimised biased glucagon-like peptide-1 receptor agonists.
Lucey M; Pickford P; Bitsi S; Minnion J; Ungewiss J; Schoeneberg K; Rutter GA; Bloom SR; Tomas A; Jones B
Mol Metab; 2020 Jul; 37():100991. PubMed ID: 32278079
[TBL] [Abstract][Full Text] [Related]
8. Ligand-Specific Factors Influencing GLP-1 Receptor Post-Endocytic Trafficking and Degradation in Pancreatic Beta Cells.
Fang Z; Chen S; Manchanda Y; Bitsi S; Pickford P; David A; Shchepinova MM; Corrêa IR; Hodson DJ; Broichhagen J; Tate EW; Reimann F; Salem V; Rutter GA; Tan T; Bloom SR; Tomas A; Jones B
Int J Mol Sci; 2020 Nov; 21(21):. PubMed ID: 33182425
[TBL] [Abstract][Full Text] [Related]
9. Exendin-4 improves behaviorial deficits via GLP-1/GLP-1R signaling following partial hepatectomy.
Zhou Y; Li Z; Cao X; Ma H; White PF; Xu X; Jiang Y; Sun X; Cui Y
Brain Res; 2019 Mar; 1706():116-124. PubMed ID: 30408479
[TBL] [Abstract][Full Text] [Related]
10. The GLP-1R as a model for understanding and exploiting biased agonism in next-generation medicines.
Douros JD; Mokrosinski J; Finan B
J Endocrinol; 2024 May; 261(2):. PubMed ID: 38451873
[TBL] [Abstract][Full Text] [Related]
11. Crystal structure of the ligand-bound glucagon-like peptide-1 receptor extracellular domain.
Runge S; Thøgersen H; Madsen K; Lau J; Rudolph R
J Biol Chem; 2008 Apr; 283(17):11340-7. PubMed ID: 18287102
[TBL] [Abstract][Full Text] [Related]
12. The Interplay of Glucagon-Like Peptide-1 Receptor Trafficking and Signalling in Pancreatic Beta Cells.
Marzook A; Tomas A; Jones B
Front Endocrinol (Lausanne); 2021; 12():678055. PubMed ID: 34040588
[TBL] [Abstract][Full Text] [Related]
13. Signalling, trafficking and glucoregulatory properties of glucagon-like peptide-1 receptor agonists exendin-4 and lixisenatide.
Pickford P; Lucey M; Fang Z; Bitsi S; de la Serna JB; Broichhagen J; Hodson DJ; Minnion J; Rutter GA; Bloom SR; Tomas A; Jones B
Br J Pharmacol; 2020 Sep; 177(17):3905-3923. PubMed ID: 32436216
[TBL] [Abstract][Full Text] [Related]
14. Exendin-4, a glucagon-like peptide-1 receptor agonist, inhibits cell apoptosis induced by lipotoxicity in pancreatic β-cell line.
Wei Q; Sun YQ; Zhang J
Peptides; 2012 Sep; 37(1):18-24. PubMed ID: 22776329
[TBL] [Abstract][Full Text] [Related]
15. Distinct roles of the extracellular surface residues of glucagon-like peptide-1 receptor in β-arrestin 1/2 signaling.
Lei S; Meng Q; Liu Y; Liu Q; Dai A; Cai X; Wang MW; Zhou Q; Zhou H; Yang D
Eur J Pharmacol; 2024 Apr; 968():176419. PubMed ID: 38360293
[TBL] [Abstract][Full Text] [Related]
16. Insulin and IGF-1 receptor autocrine loops are not required for Exendin-4 induced changes to pancreatic β-cell bioenergetic parameters and metabolism in BRIN-BD11 cells.
Rowlands J; Cruzat V; Carlessi R; Newsholme P
Peptides; 2018 Feb; 100():140-149. PubMed ID: 29412813
[TBL] [Abstract][Full Text] [Related]
17. Abolishing β-arrestin recruitment is necessary for the full metabolic benefits of G protein-biased glucagon-like peptide-1 receptor agonists.
Hinds CE; Peace E; Chen S; Davies I; El Eid L; Tomas A; Tan T; Minnion J; Jones B; Bloom SR
Diabetes Obes Metab; 2024 Jan; 26(1):65-77. PubMed ID: 37795639
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of Cu-64 and Ga-68 Radiolabeled Glucagon-Like Peptide-1 Receptor Agonists as PET Tracers for Pancreatic β cell Imaging.
Bandara N; Zheleznyak A; Cherukuri K; Griffith DA; Limberakis C; Tess DA; Jianqing C; Waterhouse R; Lapi SE
Mol Imaging Biol; 2016 Feb; 18(1):90-8. PubMed ID: 25987465
[TBL] [Abstract][Full Text] [Related]
19. GLP-1 receptor agonists stimulate ANGPTL8 production through the PI3K/Akt pathway in a GLP-1 receptor-dependent manner.
Liu J; Yang K; Xiao W; Le Y; Lang S; Zhang J; Wei R; Yang J; Hong T
Peptides; 2018 Aug; 106():83-90. PubMed ID: 30003931
[TBL] [Abstract][Full Text] [Related]
20. A Targeted RNAi Screen Identifies Endocytic Trafficking Factors That Control GLP-1 Receptor Signaling in Pancreatic β-Cells.
Buenaventura T; Kanda N; Douzenis PC; Jones B; Bloom SR; Chabosseau P; Corrêa IR; Bosco D; Piemonti L; Marchetti P; Johnson PR; Shapiro AMJ; Rutter GA; Tomas A
Diabetes; 2018 Mar; 67(3):385-399. PubMed ID: 29284659
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
